DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

What is the purpose of this trial?

This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.


Participation Guidelines

Ages: 18 years and older

Gender: Both


Southwest Oncology Group (SWOG)

Start Date: 11/20/2017

End Date: 08/31/2020

Last Updated: 12/04/2018

Study HIC#: 2000020739

Get Involved

For more information about this study, contact:
Matthew Piscatelli
+1 203-737-8367
matthew.piscatelli@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image